GREY: Tablets and injections for the licenced indication of chemotherapy/radiotherapy induced nausea and vomiting
GREY after consultant/specialist initiation: for off-licence use in hyperemesis gravidarum (the specialist to specify the dose and length of treatment for the patient). See MHRA Drug Safety Update (Jan 2020) - small increased risk of oral clefts following use in the first 12 weeks of pregnancy.
GREY after consultant/specialist initiation: For IBS associated diarrhoea. Female patients will be advised to stop ondansetron during their first trimester; QTc interval check in appropriate patients will be carried out by secondary care prior to handing over to primary care. See primary care management of IBS guidance (Decision date - July 2021)